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Abstract
Background
Transcatheter aortic valve implantation (TAVI) has become the treatment of choice in
patients with severe aortic valve stenosis who are not eligible for operative replacement and
an alternative for those with high surgical risk. Due to high age and smoking history in a high
proportion of TAVI patients, suspicious findings are frequently observed in pre-procedural
chest computer tomography (CCT).
Methods
CCT scans of 484 consecutive patients undergoing TAVI were evaluated for incidentaly
discovered solitary pulmonary nodules (SPN).
Results
In the entire study population, SPN 5 mm were found in 87 patients (18%). These patients
were compared to 150 patients who were incidentaly colected from the 397 patients with-
out SPN or with SPN<5 mm (control group). After a median folow-up of 455 days, lung
cancer was diagnosed in only two patients. Neither SPN 5 mm (p = 0.579) nor SPN>8
mm (p = 0.328) were significant predictors of overal survival.
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Conclusions
Despite the high prevalence of SPNs in this single center TAVI cohort lung cancer incidence
at midterm folow-up seems to be low. Thus, aggressive diagnostic approaches for inciden-
taly discovered SPN during TAVI evaluation should not delay the treatment of aortic steno-
sis. Unless advanced thoracic malignancy is obvious, the wel documented reduction of
morbidity and mortality by TAVI outweighs potentialy harmful delays regarding further diag-
nostics. Standard guideline-approved procedure for SPN can be safely performed after
TAVI.
Introduction
Lung cancer remains one of the world’s most common and most lethal cancer types [1]. To
reduce incidence and mortality rates of lung cancer, both improved smoking prevention pro-
grams and early clarification of suspicious radiologic findings are essential. To improve lung
cancer screening and prevention, the National Lung Screening Trial (NLST) Research Team
evaluated, whether low-dose computed tomography based screening programs for patients at
risk can reduce lung cancer mortality [2]. With regard to this evaluation, computer tomogra-
phy based screening can be recommended for wel-defined subgroups, such as heavy smokers
in between 55 to 74 years [3]. Compared to colorectal cancer screening for example, improved
prognostic efects of mass screening might therefore not be indicated for patients lacking spe-
cific risk constelations. Moreover, the most eficient diagnostic approach for routine screening
is also not clarified, yet. One major clinical problem of computed tomography based screening
is related to a high sensitivity but a rather low specificity of newly detected SPN to indicate
malignant tumors [4].
Among suspicious radiologic findings especialy solitary pulmonary nodules (SPN), lymph-
adenopathy (LAP) and pleural efusions (PE) are of clinical relevance. With regard to the size,
pulmonary lesions with a diameter of less than 3 cm and which are completely surrounded by
parenchyma are defined as SPN, whereas the term“tumor mass”refers to lesions above 3 cm
in size [5,6]. The diferential diagnosis includes both benign lesions (e.g. hamartoma or granu-
loma [5,7]) and malignant primary tumors [6] or secondary tumors [8]. Often, SPN are found
incidentaly on routine chest X-rays. One study (n = 25.529 patients above 35 years) found a
prevalence of SPN of 2% in chest X-rays [9]. In this study the number of incidentaly discov-
ered SPN on CT scans was even higher with 17% [9]. Published incidence rates for incidentaly
discovered SPN on chest CT scans and the number of diagnosed lung cancer cases are summa-
rized inTable 1.
On the basis of nodule size and risk profile (low-risk patientvs. high-risk patient), the
Fleischner Society published guidelines for the folow-up and clinical management of inciden-
taly discovered SPN [10]. At present, the diagnostic work-up covers positron emission tomog-
raphy [11,12,13], transbronchial needle aspiration [14,15,16], transthoracic needle biopsies
[17,18] and surgical intervention [19,20]. In case of low probability for malignant transforma-
tion, CT surveilance strategies are favored[6,10,21], with the potential risk of delayed onset of
treatment (Fig 1). Of interest, chest X-rays should never be used to exclude SPN [9].
Due to rising life expectancy in Germany (htp:/www.destatis.de; Federal Statistical Ofice
of Germany), incidence rates of degenerative valvular heart diseases are rising, too [22] Thera-
peuticaly, transcatheter aortic valve implantation (TAVI) has become the treatment of choice
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in patients with severe aortic valve stenosis who are not eligible for operative replacement
[23,24]. Evaluation of the TAVI candidates is a multidisciplinary process [25]. Pre-procedural
TAVI evaluation requires invasive ascending and descending aortography and or CT angiogra-
phy [26]. In line with the up-coming of this technique, the number of incidentaly discovered
SPN in pre-procedural CT scans has risen.
Here we present single center data upon the prevalence, clinical folow-up and possible
impact on therapeutic decision of incidentaly discovered SPN and thoracic malignancies in
patients under evaluation for transcatheter aortic valve implantation.
Methods
Study population
Before data colection, approval from the joint Ethical Commitee of the Faculty of Medicine of
the Westfalian Wilhelms-University Münster and the Physicians Chamber of Westfalia-Lippe
was obtained (application number: 2015-037-f-S). Since the data colection was retrospective,
writen consent was considered as not necessary. Patient information was anonymized and de-
identified prior to analysis. For al included patients, TAVI evaluation was performed at the
Department of Cardiovascular Medicine, Division of Adult Congenital and Valvular Heart
Disease, University Hospital Münster, Germany. To assess the overal incidence of suspicious
radiologic findings in our study colective, an overal screening for solitary pulmonary nodules
(SPN), lymphadenopathy (LAP) and pleural efusions (PE) was performed in 484 consecutive
patients. SPN 5 mm were found in 87 patients (18%). From the remaining 397 patients with-
out SPN or with SPN<5 mm, 150 patients were incidentaly colected for comparison (control
group,Fig 2). Baseline characteristics of the two groups (i.e. patients without SPN or SPN<4
mmvs. patients with SPN 5 mm) are demonstrated inTable 2. Computed power of 57.2%
for both groups of patients was calculated using Statistical Analysis System (SAS Institute,
Cary, NC, USA).
Radiological CT imaging
CT Angiography (CTA) was performed at the Department of Clinical Radiology using dual
source 64 and 128 slice CT scanners (Somatom Definiton and Somatom Definition Flash, Sie-
mens AG, Medical Solutions, Forchheim, Germany) with a tube voltage of 120 kV and a coli-
mation of 64/128 x 0.6 mm using an atenuation-based tube current modulation (CARE
Table 1. The incidence of incidentaly discovered SPN (cases on chest computer tomographies) and the number of diagnosed lung cancer cases.
Author Study patients (n) Age (years) Study population SPN (%) Lung cancer (%)
Onuma et al. 2006 [34] 503 66 Patients with suspected coronary artery disease 16.7 0.8
Haler et al. 2006 [39] 166 64 Patients with suspected coronary artery disease n.e.* 1.2
Müler et al. 2007 [35] 259 64 Patients after coronary artery bypass grafting surgery 3.5 0.4
Burt et al. 2008 [36] 459 65 Patients with suspected coronary artery disease 28 n.e.*
Machaalany et al. 2009 [37] 966 58 Patients with suspected coronary artery disease 23** 0.3
Gómez-Sáez et al. 2014 [9] 2427 66 non-high-risk population 17 n.e.*
Stachon et al. 2015 [38] 374 80 Patients under evaluation for TAVR 4.3 n.e.*
Schmidt et al. 2016 484 82 Patients under evaluation for TAVR 18 0.6
*n.e. = not evaluable.
**granulomata included.
doi:10.1371/journal.pone.0155398.t001
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dose4DTM, Siemens AG, Medical Solutions, Forchheim, Germany) to reduce radiation
exposure.
Adapted to the patient’s constitution and renal function 60–100 ml i.v. contrast agent
(Imeron 370, Bracco Imaging, Milano, Italy) were administered at a constant injection rate of
3–4 ml/sec. Folowing bolus triggered start (+140 HU, measured in the ascending aorta)
images of the aortic root are acquired ECG-gated with a dose modulation, reducing the tube
current between 80% and 20% of the R-R-cycle to 20%. Subsequently the whole thoraco-
abdominal aorta including the inguinal arteries is acquired in one helical scan without ECG-
synchronization.
Al images were reconstructed in transverse orientation with a slice thickness of 1 mm and
an increment of 0.6 mm for further evaluation. The ECG-gated dataset of the aortic root was
additionaly reconstructed in 10% steps, covering the whole R-R-cycle.
Fig 1. Diagnostic strategies for incidentaly discovered solitary pulmonary nodules (adapted from: Gould et al. 2013).
doi:10.1371/journal.pone.0155398.g001
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Statistical Analysis
The study population was described by standard descriptive statistical measures. For categori-
cal variables, absolute and relative frequencies are reported. For continuous variables median
and interquartile range (IQR) are reported, respectively. To compare both tested groups (i.e.
patients without SPN or SPN<5mmvs. patients with SPN 5 mm) p-values for continuous
parameters were calculated using Mann-Whitney-U-test and likewise for categorical variables
Chi-square test or Fisher’s exact test were applied, respectively. Similar, associations of clinico-
pathological parameters with SPN were tested using two-sided Fisher’s exact test. Univariate
overal survival analysis was performed using the Kaplan-Meier method and Log-rank tests. A
multivariable Cox proportional hazard model was fited using a forward step-wise variable
selection (inclusion criteria: p-value of the likelihood ratio test 0.05) to identify independent
prognostic factors for overal survival. We considered potential prognostic factors that are tol-
erably complete (less than ten missing values, and with at least ten cases), to prevent statistical
problems emerging from low sample size and extreme values. Patients with missing values in
the cofactors were excluded from the analysis.
Al statistical tests were performed as exploratory analyses on a local significance level of
0.05. Since multiplicity adjustment was not carried out, no distinct overal significance level
was ascertained. Hence, our findings may be used to set up new hypotheses. The statistical soft-
ware SPSS (SPSS Statistics, Version 22.0 released 2013, IBM Corp., Armonk, NY) was used for
al analyses.
Results
Study colectives and patient selection
Prevalence of SPN 5 mm on pre-procedural CT scans was 18% (n = 87) in the 484 patients,
who were evaluated for TAVI eligibility at Münster University Hospital. Median age of the
Fig 2. Study colective and tested clinical subgroups.The flow diagram demonstrates the selection of the tested subgroups (*control group includes
both patients without detected SPN and those patients with SPN<5mm).
doi:10.1371/journal.pone.0155398.g002
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entire study population was 82 years and 202 were male (42%). Of interest, n = 111 patients
(23%) had a malignant disease in the past and 3 patients were diagnosed for lung cancer folow-
ing pre-procedural evaluation. Al identified lung cancer patients were male smokers and had
suspicious radiologic findings (i.e. patient #1: SPN of 16 mm size; patient #2: SPN of 21 mm
size and lymphadenopathy; patient #3: No SPN, but tumor mass of 6.2 cm x 4 cm and lymph-
adenopathy). On last contact, al of them were stil alive. However, TAVI was only performed
on patient #1 and on patient #2.
For further diagnostic and prognostic analyses al those patients with incidentaly discovered
SPN 5 mm (n = 87) and n = 150 patients either without SPN or with SPN<5 mm (serving
as the control population) were chosen (computed power: 57.2%). Depending on the size of
SPN, n = 61 patients had SPN of 5–8 mm and n = 26 patients had SPN of>8 mm size. Of the
identified three lung cancer patients, only two patients had SPN by definition. Even though
patient #3 was also diagnosed with lung cancer, this patient was excluded from further statistical
analyses due to the initial discovery of a“tumor mass”in the pre-procedural CT scan.
Table 2. Baseline characteristics of patients under TAVI evaluation with complete folow-up data (n = 237 patients).
Patients with SPN 5mm
(n = 87)
Patients without SPN or SPN<5mm
(n = 150)
p-values*for the comparison of both
tested groups
Clinical parameters
Median age, years (Q1–Q3) 83 (77–87) 82 (78–86) 0.571
Male gender, N(%) 37 (43%) 63 (42%) 0.937
Respiratory parameters
Smoking history N(%) 26 (52%) 47 (38%) 0.096
Median FEV1% (Q1–Q3) 78% (62%-94%) 77% (64%-97%) 0.380
Cardiologic parameters
LVEF, N(%) 0.148
>55% 61 (72%) 89 (60%)
45–54% 6 (7%) 21 (14%)
30–44% 13 (15%) 21 (14%)
<30% 5 (6%) 17 (12%)
Median aortic valve
Area, cm² (Q1–Q3)
0.6 (0.5–0.8) 0.6 (0.5–0.8) 0.966
TAVI performed, N (%) 70 (81%) 133 (89%) 0.082
Radiologic parameters
Solitary pulmonary nodule,
N(%)
<0.0001
<5 mm 0 (0%) 44 (29%)
5–8 mm 61 (70%) 0 (0%)
>8 mm 26 (30%) 0 (0%)
Lymphadenopathy, N(%) 18 (21%) 48 (32%) 0.061
Pleural efusions, N(%) 15 (17%) 31 (21%) 0.520
Previous malignancy, N(%) 20 (23%) 39 (26%) 0.605
Lung cancer diagnosis,
N (%)
2 (3%) 0 (0%) 0.342
Median folow-up, days
(Q1–Q3)
406 (233;603) 495 (307;859) 0.012
*p-values for the comparison of both tested groups (i.e. patients without SPN or SPN<5mmvs. patients with SPN 5 mm).
For continuous parameters Mann-Whitney-U-test and for categorical variables Chi-square test or Fisher’s exact test, respectively were applied.
doi:10.1371/journal.pone.0155398.t002
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Baseline characteristics for both tested study colectives (in total n = 237 patients: n = 150
patients without SPN or SPN<5mmvs. n = 87 patients with SPN 5 mm) are summarized
inTable 2. Regarding equal distribution of the two tested study colectives, no significant difer-
ence was found for the evaluated variables (e.g. age, gender or smoking history). Since the SPN
size was command variable, a significant diference was found (p<0.0001).
Clinical associations for identified SPN
For the 237 study patients associations of clinical and respiratory parameters with suspicious
radiologic findings (i.e. SPN 5 mm, SPN>8 mm, LAP and PE) were investigated. Here,
smoking history was positively associated with SPN>8 mm (p = 0.033). Suspicious lymphade-
nopathy was found more often for patients below 80 years in contrast to patients above 80
years (39%vs. 23%; p = 0.013) and for men in contrast to women (36%vs. 22%; p = 0.019). For
al other tested variables no other relevant correlations with SPN, LAP or PE were found (al
p>0.05;Table 3).
Univariate prognostic efects
Using Log-rank test, prognostic impact of SPN 5 mm and of SPN 8 mm in patients under
TAVI evaluation with complete folow-up data (n = 237 patients) was investigated. Neither for
SPN 5 mm nor for SPN 8 mm prognostic efects were found in these univariate analyses
(al p>0.05,Table 4andFig 3). In addition, prognostic analyses were also performed for sus-
picious lymphadenopathy (p>0.05;Table 4andFig 3) and pleural efusions (p = 0.042;
Table 4andFig 3).
Multivariate prognostic efects
Cox proportional hazards models for comparison with established prognostic factors was used
to identify prognostic impact in a multivariate seting. Included variables were: gender (male
(ref.)vs. female), age (<80 years (ref.)vs. 80 years), left ventricular ejection fraction (both as
continuous variable and as categorical variable (LVEF<45% (ref.)vs. LVEF 45%)), previous
malignancy (no previous malignancy (ref.)vs. previous malignancy), solitary pulmonary nod-
ules (no SPN (ref.)vs. SPN 5 mm and al others (ref.)vs. SPN>8 mm), lymphadenopathy
(no LAP (ref.)vs. LAP) and pleural efusions (no PE (ref.)vs. PE).
As shown before in the univariate analyses, SPN 5 mm or SPN>8 mm were not identi-
fied as independent prognostic factors (p 0.05;Table 5). However, left ventricular ejection
fraction was found to be of prognostic relevance for overal survival (HR [95% CI] = 2.194
Table 3. Correlations of clinical and respiratory parameters with suspicious radiologic findings (i.e. SPN, LAP and PE) for patients under TAVI
evaluation with complete folow-up data (n = 237 patients).
p-values according to Fisher’s exact test
SPN 5mm (n = 87) SPN>8mm (n = 26) LAP (n = 66) PE (n = 46)
Clinical parameters
Age (<80 yearsvs. 80 years) 0.667 0.510 0.013 0.053
Sex (malevs. female) 1.000 0.097 0.019 0.621
Respiratory parameters
Smoking history (non-smokersvs. smokers) 0.126 0.033 0.741 0.414
FEV1% (FEV 80%vs. FEV1<80%) 0.741 0.318 0.727 0.401
Previous malignancy 0.643 0.632 0.180 1.000
doi:10.1371/journal.pone.0155398.t003
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[1.220–3.947]; p = 0.009;Table 5). This observation was next confirmed using log rank test
(p = 0.004;Fig 4).
Discussion
Both the diagnostic and therapeutic management of incidentaly discovered SPN depends on
the evaluation of malignant probability. Therefore, risk factors such as smoking habits or
work-related exposures need to be considered. Next, the exact description of shape and size is
important. The bigger the nodule, the higher the chance for malignant transformation [10,27–
31]. Likewise, information regarding location [30], growth [32] and shape [33] should be
respected, too. Predictive models such as the Mayo Clinic model (derived from chest X-rays
with focus on age, smoking status, history of malignancy, SPN size, shape and location [27]) or
computer-based calculation programs (e.g.htp:/chestx-ray.com/index.php/calculators/spn-
calculator) can facilitate risk stratification.
Although the number of elderly patients who require TAVI implantation is growing [24],
there are neither evidence based recommendations nor clinical guidelines to decide upon the
further therapeutic procedure of incidentaly discovered SPN during pre-procedural TAVI
evaluation. Hence, there is a growing demand for interdisciplinary decisions on priorities for
further diagnostic versus therapeutic procedures in these patients.
To address this clinical problem, we evaluated pre-procedural CT scans of 484 patients with
focus on solitary pulmonary nodules (SPN). SPN of at least 5 mm size were found in 18% in
the initial study colective. This ratio corresponds wel to other published studies, which
reported incidence rates ranging from 3.5% to 28% [9,34–39].
To investigate the prognostic impact of SPN in patients who were under investigation for
TAVI eligibility, we included only those 87 patients with incidentaly discovered SPN 5mm
Table 4. Prognostic analysis for suspicious radiologic findings (i.e. SPN, LAP and PE) in patients under TAVI evaluation with complete folow-up
data (n = 237 patients).
p-value according to log rank test
SPN 5mm (n = 87) SPN>8mm (n = 26) LAP (n = 66) PE (n = 46)
Al patients, ful study colective 0.579 0.328 0.982 0.042
Subgroup: Clinical parameters
Age
<80 years 0.268 0.382 0.824 0.015
80 years 0.179 0.521 0.798 0.257
Sex
male 0.227 0.677 0.959 0.140
female 0.716 0.057 0.984 0.214
Subgroup: Respiratory parameters
Smoking
never-smokers 0.206 0.383 0.575 0.954
smokers 0.347 0.579 0.645 0.083
FEV1%
FEV1 80% 0.663 0.799 0.824 0.040
FEV1<80% 0.468 0.969 0.712 0.991
Previous malignancy
no previous malignancy 0.299 0.560 0.987 0.035
previous malignancy 0.472 0.279 0.938 0.749
doi:10.1371/journal.pone.0155398.t004
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and colected 150 control patients either without SPN or with SPN<5 mm. For al these
patients (n = 237 patients in total) complete folow-up data were assigned and clinical correla-
tions were studied. Besides, lymphadenopathy was found in 28% and pleural efusions in 19%
of the investigated patients. Upon further diagnostics, 0.6% of the patients developed lung can-
cer. This ratio corresponds wel to other reported ratios ranging from 0.3% to 1.2% [34–
35,37,39].
Fig 3. Prognostic impact of solitary pulmonary nodules (SPN), lymphadenopathy (LAP) and pleural efusions (PE) in patients
under evaluation for TAVI (n = 237 patients).Kaplan Meier charts are given for SPN 5mm (A), for SPN>8mm (B), for LAP (C) and for
PE (D).
doi:10.1371/journal.pone.0155398.g003
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With regard to clinical correlations, no relevant associations were found for SPN 5. For
smoking history however, a positive association with larger SPN of>8 mm was observed. This
association is also supported by another study group [9]. Besides, we found positive associa-
tions for lymphadenopathy with age and gender. To our knowledge, there are no other studies,
which contribute to this observation. Potentialy, this observation might only hint to a beter
general health status of women compared to men above the age of 80 years in our study colec-
tive. Hence, we also investigated the prognostic impact of gender on overal survival. However,
for the investigated study colective we cannot report a relevant prognostic impact of gender on
overal survival (data not shown).
Regarding prognosis, the incidence of SPN did not afect overal survival neither within the
investigated entire study colective nor within clinical subgroups. In the univariate model,
prognostic efects were found for pleural efusions in the ful study colective and even stronger
Table 5. Overal survival: Explanatory prognostic factors in a Cox proportional Hazards model for the
selected study colective.Included variables: sex (male (ref.)vs. female), age (<80 years (ref.)vs. 80
years), LVEF (as a continuous variable), LVEF (LVEF<45% (ref.)vs. 45%); previous malignancy (no previ-
ous (ref.) malignancyvs. previous malignancy); SPN (no SPN (ref.)vs. SPN 5 mm and al others (ref.)vs.
SPN>8 mm), lymphadenopathy (no lymphadenopathy (ref.)vs. lymphadenopathy) and pleural efusions (no
pleural efusions (ref.)vs. pleural efusions).
Identiﬁed prognostic factor p-Value* HR1(95% CI)2
LVEF 0.009 2.194 (1.220–3.947)
1HR = hazard ratio: HR<1 indicates improved survival.
2CI = conﬁdence interval.
*p value indicates model improvement (likelihood ratio test).
doi:10.1371/journal.pone.0155398.t005
Fig 4. Prognostic impact of left ventricular ejection fraction (LVEF) in the ful study colective
(p = 0.004).Overal survival of those patients with a LVEF 45% was increased compared to those patients
with a LVEF<45%.
doi:10.1371/journal.pone.0155398.g004
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efects within the tested prognostic subgroups stratified for age, impaired FEV1 and a history
of previous malignancies. In general, pleural efusions can be found in various clinical condi-
tions. Besides, rheumatoid, infectious or malignant diseases [40], pleural efusions are often
associated with cardiac failure [41]. Hence, the prognostic impact of pleural efusions might
rather reflect cardiac failure in this population. In our study colective impaired LVEF was asso-
ciated with pleural efusions (data not shown). This hypothesis can also be supported by the
observed prognostic impact of LVEF both in the univariate and in the multivariate analysis.
With regard to this prognostic approach, further diagnostic procedures for incidentaly dis-
covered SPN delaying TAVI evaluation may not yield in improved prognosis for this patient
colective and delay symptom amelioration and prognostic efects of TAVI. Similar to our
approach, another research group focused on suspicious incidental radiological findings in 414
participants screened either for surgical aortic valve replacement or TAVI with dual-source CT
scans [38]. According to their study, suspicious incidental radiological findings did not signifi-
cantly influence further therapeutic decisions [odds ratio (OR) 1.14; P = 0.835] or time to treat-
ment (91 ± 152vs. 61 ± 109 days, respectively). Moreover, overal survival two years after
decision to intervene did not difer significantly (p>0.05, [38]). The decision for treatment was
made according to the guidelines for TAVI, which recommend the procedure only in patients
with an estimated survival of 1 year at least [42]. Besides, decisions should be made up by inter-
disciplinary teams [42]. Our analysis indicates a need for more specific clinical recommenda-
tions or guidelines to decide on the further evaluation of patients at risk with newly detected
SPN. Potentialy, CT folow-up scans for patients with SPN in a good clinical status (i.e. NHYA
I) might therefore be recommended after a period of six months. Otherwise, our results as wel
as other published results argue in favor of the notion, that standard guideline-approved proce-
dures for SPN can be safely performed after TAVI. Besides its single-center nature, the retro-
spective study design and the interdisciplinary selection for TAVI intervention our study does
have its limitations. However our results may be helpful in management of patients evaluated
for TAVI who present with suspicious radiologic findings.
In conclusion, we were able to demonstrate, that the overal survival of those patients, who
are under evaluation for TAVI was not afected by incidentaly detected SPN. Thus, aggressive
diagnostic approaches for incidentaly discovered SPN during TAVI evaluation should not
delay the treatment of aortic stenosis. Unless advanced thoracic malignancy is obvious, the wel
documented reduction of morbidity and mortality of severe symptomatic aortic stenosis by
TAVI outweighs potentialy harmful delays regarding further diagnostics. Standard guideline-
approved procedure for SPN can be safely performed after TAVI.
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